Skip to content

Study · Observational study · n = 174 · 2025

6 results

Recurrent weight gain after sleeve gastrectomy: conversion to Roux-en-Y gastric bypass versus novel GLP-1 s.

Wasden K, Mathur V, Martin TJ, Shin TH, Nimeri AA, Tavakkoli A, Sheu EG

Surgical endoscopy2 Jul 2025Cited by 3 (Europe PMC)

PMID40603615 (opens in a new tab)DOI10.1007/s00464-025-11910-2 (opens in a new tab)PepBankPUB-40603615
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with recurrent weight gain after sleeve gastrectomy, semaglutide gave less total weight loss at two years than Roux-en-Y gastric bypass (7.6% versus 17.1%).

    In plain wordsIn patients who regained weight after sleeve surgery, semaglutide led to less weight loss at two years than gastric bypass surgery.

    Peptide
    Semaglutide
    Outcome
    DecreaseTotal weight loss at two years
    Study

    n = 174

    Comparator
    Roux-en-Y gastric bypass
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Total weight loss
    7.6%
    semaglutide cohort

    Source sentences

    Summary
    %TWL two years post-intervention was greater in the RYGB compared to the semaglutide cohort (17.1% vs. 7.6%, mean difference = 9.5%, 95% CI [2.6, 16.4], p = 0.002
    1 context sentence
    Summary · context
    Patients at a tertiary care hospital who underwent RYGB conversion after SG (n = 87) were matched 1:1 to SG patients treated with semaglutide (n = 87) by: age, gender, race, ethnicity, pre-SG to pre-intervention total weight loss (%TWL), BMI, diabetes status, and time between SG and intervention.
  2. 02HumanObservational studyEfficacy outcome

    In patients with recurrent weight gain after sleeve gastrectomy, fewer patients on semaglutide than after gastric bypass achieved more than 10% total weight loss (40.9% versus 82.6%).

    In plain wordsIn patients who regained weight after sleeve surgery, fewer on semaglutide than after gastric bypass lost more than 10% of their weight.

    Peptide
    Semaglutide
    Outcome
    DecreaseProportion with more than 10% total weight loss
    Study

    n = 174

    Comparator
    Roux-en-Y gastric bypass
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Proportion with >10% TWL
    40.9%
    semaglutide cohort

    Source sentences

    Summary
    %TWL two years post-intervention was greater in the RYGB compared to the semaglutide cohort (17.1% vs. 7.6%, mean difference = 9.5%, 95% CI [2.6, 16.4], p = 0.002), as was the proportion of patients who achieved > 10% TWL (82.6% v. 40.9%, p < 0.001).
    1 context sentence
    Summary · context
    Patients at a tertiary care hospital who underwent RYGB conversion after SG (n = 87) were matched 1:1 to SG patients treated with semaglutide (n = 87) by: age, gender, race, ethnicity, pre-SG to pre-intervention total weight loss (%TWL), BMI, diabetes status, and time between SG and intervention.
  3. 03HumanObservational studyEfficacy outcome

    In patients with recurrent weight gain after sleeve gastrectomy, diabetes medications did not decrease significantly in the semaglutide cohort, unlike after gastric bypass.

    In plain wordsIn patients who regained weight after sleeve surgery, diabetes medicine use did not fall significantly with semaglutide, unlike after gastric bypass.

    Peptide
    Semaglutide
    Outcome
    No significant changeDiabetes medication use
    Study

    n = 174

    Comparator
    Roux-en-Y gastric bypass
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Diabetes medications (p = 0.018) and mean HbA1c (p = 0.006) decreased significantly in the RYGB but not semaglutide cohort.
    1 context sentence
    Summary · context
    Patients at a tertiary care hospital who underwent RYGB conversion after SG (n = 87) were matched 1:1 to SG patients treated with semaglutide (n = 87) by: age, gender, race, ethnicity, pre-SG to pre-intervention total weight loss (%TWL), BMI, diabetes status, and time between SG and intervention.
  4. 04HumanObservational studyEfficacy outcome

    In patients with recurrent weight gain after sleeve gastrectomy, mean HbA1c did not decrease significantly in the semaglutide cohort, unlike after gastric bypass.

    In plain wordsIn patients who regained weight after sleeve surgery, HbA1c did not fall significantly with semaglutide, unlike after gastric bypass.

    Peptide
    Semaglutide
    Outcome
    No significant changeHbA1c
    Study

    n = 174

    Comparator
    Roux-en-Y gastric bypass
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Diabetes medications (p = 0.018) and mean HbA1c (p = 0.006) decreased significantly in the RYGB but not semaglutide cohort.
    1 context sentence
    Summary · context
    Patients at a tertiary care hospital who underwent RYGB conversion after SG (n = 87) were matched 1:1 to SG patients treated with semaglutide (n = 87) by: age, gender, race, ethnicity, pre-SG to pre-intervention total weight loss (%TWL), BMI, diabetes status, and time between SG and intervention.
  5. 05HumanObservational studySafety outcome

    In patients with recurrent weight gain after sleeve gastrectomy, the semaglutide cohort had fewer gastrointestinal surgeries and endoscopies than the gastric bypass cohort.

    In plain wordsIn patients who regained weight after sleeve surgery, those on semaglutide needed fewer stomach or bowel procedures than those who had gastric bypass.

    Peptide
    Semaglutide
    Outcome
    DecreaseGastrointestinal surgeries and endoscopies
    Study

    n = 174

    Comparator
    Roux-en-Y gastric bypass
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    RYGB patients had increased frequencies of GI surgeries and endoscopies.
  6. 06HumanObservational studyEfficacy outcome

    In patients with recurrent weight gain after sleeve gastrectomy, two-year total weight loss in semaglutide responders (22.9%) was similar to that after gastric bypass (17.1%).

    In plain wordsIn patients who regained weight after sleeve surgery, those who responded to semaglutide lost about as much weight as after gastric bypass.

    Peptide
    Semaglutide
    Outcome
    No significant changeTwo-year total weight loss in semaglutide responders
    Study

    n = 113

    Comparator
    Roux-en-Y gastric bypass
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Total weight loss
    22.9%
    semaglutide responders

    Source sentences

    Summary
    For semaglutide 'responders,' two-year %TWL was similar to RYGB (22.9% vs. 17.1%, p = 0.423).
    2 context sentences
    Summary · context
    Semaglutide 'responders' (defined as ≥ 5% TWL at three months, n = 26) and non-responders were similarly compared to the overall RYGB cohort.
    Summary · context
    Patients at a tertiary care hospital who underwent RYGB conversion after SG (n = 87) were matched 1:1 to SG patients treated with semaglutide (n = 87) by: age, gender, race, ethnicity, pre-SG to pre-intervention total weight loss (%TWL), BMI, diabetes status, and time between SG and intervention.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.